インスリン送達デバイス市場の規模：タイプ別、エンドユーザー別- 地域的展望、競合戦略、セグメント予測 (～2033年)

インスリン送達デバイスの市場規模は、予測期間中にCAGR 8.71%で推移し、2033年には701億4,000万米ドルの規模に成長すると予測されています。

インスリン送達デバイスの市場は、COVID-19の流行によって大きな影響を受けました。I型糖尿病患者はCOVID-19の影響をより強く受けます。すでに免疫系が低下しているため、COVID-19にさらされると急速に悪化します。また、健康な人よりも重大な合併症にかかりやすい可能性があります。

当レポートでは、世界のインスリン送達デバイスの市場を調査し、市場概要、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

• 促進要因・抑制・機会・課題の分析
• COVID-19による市場への影響

第5章 市場変数と見通し

• SWOT分析
• PESTEL分析
• ポーターのファイブフォース分析
• ヒートマップ分析

第6章 競合情勢

• 製造拠点の分布・販売エリア・製品タイプ
• M&A・提携・製品発売・協力

第7章 インスリン送達デバイス市場：タイプ別

• 世界の市場規模のシェア・予測
• インスリンペン
• インスリンポンプ
• インスリン注射器
• インスリンペン針

第8章 インスリン送達デバイス市場：エンドユーザー別

• 世界の市場規模のシェア・予測
• 病院・クリニック
• 患者・在宅ケア

第9章 インスリン送達デバイス市場の予測

• 市場規模・市場シェア

第10章 インスリン送達デバイス市場：タイプ別

• 市場規模・市場シェアの推移・予測

第11章 インスリン送達デバイス市場：エンドユーザー別

• 市場規模・市場シェアの推移・予測

第12章 インスリン送達デバイス市場：地域別

• 市場規模・市場シェアの推移・予測
• 東部
• 西部
• 北部
• 南部

第13章 企業プロファイル

• Biocon Limited
• Diabetes Care Business
• Eli Lilly and Company
• Hindustan Syringes & Medical Devices Ltd.
• Insulet Corporation
• Mannkind Corporation
• Sanofi
• Terumo Corporation
• Vicentra B.V.
• Others

第14章 略語のリスト

第15章 参考リンク

第16章 総論

第17章 調査範囲

Insulin Delivery Devices Market Introduction and Overview

According to SPER market research, 'Insulin Delivery Devices Market Size- By Type, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Insulin Delivery Devices Market is predicted to reach USD 70.14 billion by 2033 with a CAGR of 8.71%.

The beta cells in the islets of Langerhans of the pancreas produce the hormone insulin. By promoting cellular glucose uptake and controlling the metabolism of fats, proteins, and carbohydrates, the hormone keeps blood glucose levels within normal ranges. Type I and type II diabetes can be brought on by inappropriate insulin function brought on by damaged beta cells or the body's incapacity to utilize the insulin that is produced.

Furthermore, the market for insulin delivery devices was significantly impacted by the COVID-19 pandemic. Patients with type 1 diabetes are more affected by COVID-19. Due to their already compromised immune systems, people with diabetes quickly deteriorate when exposed to COVID-19. Individuals with diabetes may be more susceptible than healthy individuals to major complications.

Scope of the Report:

Report Metric Details

Market size available for years 2019-2033

Base year considered 2022

Forecast period 2023-2033

Segments covered By Type, By End User.

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Biocon Limited, Eli Lilly and Company, Hindustan Syringes & Medical Devices Ltd, Insulet Corporation, Mannkind Corporation, Medtronic, Sanofi, Terumo Corporation, and Vicentra B.V.

Insulin Delivery Devices Market Segmentation:

By Type: Based on the Method type, Insulin Delivery Devices Market is segmented as; Insulin Pens (Reusable, Disposable), Insulin Pumps (Tethered, Tubeless), Insulin Syringes, Insulin Pen Needles (Standards & Safety).

By End User: Based on the End User, Insulin Delivery Devices Market is segmented as; (Hospitals & Clinics, Patients & Homecare).

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Table of Contents

1. Introduction

• 1.1. Scope of the report
• 1.2. Market segment analysis

2. Research Methodology

• 2.1. Research data source
  • 2.1.1. Secondary Data
  • 2.1.2. Primary Data
  • 2.1.3. SPER's internal database
  • 2.1.4. Premium insight from KOL's
• 2.2. Market size estimation
  • 2.2.1. Top-down and Bottom-up approach
• 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

• 4.1. Driver, Restraint, Opportunity and Challenges analysis
  • 4.1.1. Drivers
  • 4.1.2. Restraints
  • 4.1.3. Opportunities
  • 4.1.4. Challenges
• 4.2. COVID-19 Impacts of the Insulin Delivery Devices Market

5. Market variable and outlook

• 5.1. SWOT Analysis
  • 5.1.1. Strengths
  • 5.1.2. Weaknesses
  • 5.1.3. Opportunities
  • 5.1.4. Threats
• 5.2. PESTEL Analysis
  • 5.2.1. Political Landscape
  • 5.2.2. Economic Landscape
  • 5.2.3. Social Landscape
  • 5.2.4. Technological Landscape
  • 5.2.5. Environmental Landscape
  • 5.2.6. Legal Landscape
• 5.3. PORTER's Five Forces
  • 5.3.1. Bargaining power of suppliers
  • 5.3.2. Bargaining power of buyers
  • 5.3.3. Threat of Substitute
  • 5.3.4. Threat of new entrant
  • 5.3.5. Competitive rivalry
• 5.4. Heat Map Analysis

6. Competitive Landscape

• 6.1. Insulin Delivery Devices Market Manufacturing Base Distribution, Sales Area, Product Type
• 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Insulin Delivery Devices Market

7. Insulin Delivery Devices Market, By Type (USD Million)

• 7.1. Insulin Delivery Devices Market Value Share and Forecast, By Type, 2023-2033
• 7.2. Insulin Pens
• 7.3. Insulins Pumps
• 7.4. Insulin Syringes
• 7.5. Insulin Pen Needles

8. Insulin Delivery Devices Market, By End User (USD Million)

• 8.1. Insulin Delivery Devices Market Value Share and Forecast, By Vehicle type, 2023-2033
• 8.2. Hospitals & Clinics
• 8.3. Patients & Homecare

9. Insulin Delivery Devices Market Forecast, 2019-2033 (USD Million)

• 9.1. Insulin Delivery Devices Market Size and Market Share

10. Insulin Delivery Devices Market, By Type, 2019-2033 (USD Million)

• 10.1. Insulin Delivery Devices Market Size and Market Share By Type (2019-2026)
• 10.2. Insulin Delivery Devices Market Size and Market Share By Type (2027-2033)

11. Insulin Delivery Devices Market, By End User, 2019-2033 (USD Million)

• 11.1. Insulin Delivery Devices Market Size and Market Share By End User (2019-2026)
• 11.2. Insulin Delivery Devices Market Size and Market Share By End User (2027-2033)

12. Insulin Delivery Devices Market, By Region, 2019-2033 (USD Million)

• 12.1. Insulin Delivery Devices Market Size and Market Share By Region (2019-2026)
• 12.2. Insulin Delivery Devices Market Size and Market Share By Region (2027-2033)
• 12.3. Eastern Region
• 12.4. Western Region
• 12.5. Northern Region
• 12.6. Southern Region

13. Company Profile

• 13.1. Biocon Limited
  • 13.1.1. Company details
  • 13.1.2. Financial outlook
  • 13.1.3. Product summary
  • 13.1.4. Recent developments
• 13.2. Diabetes Care Business
  • 13.2.1. Company details
  • 13.2.2. Financial outlook
  • 13.2.3. Product summary
  • 13.2.4. Recent developments
• 13.3. Eli Lilly and Company
  • 13.3.1. Company details
  • 13.3.2. Financial outlook
  • 13.3.3. Product summary
  • 13.3.4. Recent developments
• 13.4. Hindustan Syringes & Medical Devices Ltd.
  • 13.4.1. Company details
  • 13.4.2. Financial outlook
  • 13.4.3. Product summary
  • 13.4.4. Recent developments
• 13.5. Insulet Corporation
  • 13.5.1. Company details
  • 13.5.2. Financial outlook
  • 13.5.3. Product summary
  • 13.5.4. Recent developments
• 13.6. Mannkind Corporation
  • 13.6.1. Company details
  • 13.6.2. Financial outlook
  • 13.6.3. Product summary
  • 13.6.4. Recent developments
• 13.7. Sanofi
  • 13.7.1. Company details
  • 13.7.2. Financial outlook
  • 13.7.3. Product summary
  • 13.7.4. Recent developments
• 13.8. Terumo Corporation
  • 13.8.1. Company details
  • 13.8.2. Financial outlook
  • 13.8.3. Product summary
  • 13.8.4. Recent developments
• 13.9. Vicentra B.V.
  • 13.9.1. Company details
  • 13.9.2. Financial outlook
  • 13.9.3. Product summary
  • 13.9.4. Recent developments
• 13.10. Others

14. List of Abbreviations

15. Reference Links

16. Conclusion

17. Research Scope